Study S001585

Effects of Antagonizing the Ghrelin Receptor in Individuals With Obesity on Treatment With Semaglutide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07171723
Acronym: SILENCED
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 24
Start: 2025-09-01
Primary completion: 2026-08-12
Lead sponsor: University Hospital, Gentofte, Copenhagen
Conditions: Obesity &Amp; Overweight
Interventions: BIOLOGICAL:Liver-Expressed Antimicrobial Peptide 2 (LEAP2); OTHER:Placebo (saline)
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Food intake [290 to 310 minutes]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.